Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy Menin combination expands backbone potential of Actimab-A in acute myeloid leukemia that already includes chemotherapy, […]
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
– Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm – In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and […]
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
NIH grant to support first of its kind clinical trial to use Antibody Radio-Conjugate for targeted conditioning prior to CAR T-cell therapy in patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma ARC-based targeted lymphodepletion is intended to improve CAR T-cell patient outcomes by selectively depleting immune cells, including those implicated in CAR […]
Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform
New York, NY – October 14, 2020 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced the launch of its new research and development lab facility in New York City . This new research facility expands Actinium’s internal R&D capabilities and will be focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC therapeutic […]
